Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study

Lancet

Volumn 359, Issue 9300, 2002, Pages 30-36

  Fellay, Jacques ^a   Marzolini, Catia ^a   Meaden, Emma R ^f   Back, David J ^f   Buclin, Thierry ^a   Chave, Jean Philippe ^a,d   Decosterd, Laurent A ^a   Furrer, Hansjakob ^b   Opravil, Milos ^c   Pantaleo, Giuseppe ^a   Retelska, Dorota ^a   Ruiz, Lidia ^g   Schinkel, Alfred H ^h   Vernazza, Pietro ^e   Eap, Chin B ^a   Telenti, Amalio ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Hospital of la Source   (Switzerland)

^e Hospital of St Gallen   (Switzerland)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CYTOCHROME; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EFAVIRENZ; GLYCOPROTEIN P; ISOENZYME; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR;

ALLELE; ARTICLE; DISEASE COURSE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; GENE; GENETIC CODE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE TRANSPORTER GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIREMIA;

EID: 0037022006     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07276-8     Document Type: Article

References (34)

1. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
2. Developmentally regulated expression of P-glycoprotein (multidrug resistance) activity in mouse thymocytes
3. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
4. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport
5. Transport, metabolism and elimination mechanisms of anti-HIV agents
6. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
7. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
8. PCR-based genotyping for duplicated and deleted CYP2D6 genes
9. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction
10. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
11. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: Probe of CYP3A
12. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
13. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
14. Nelfinavir: An update on its use in HIV infection
15. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
16. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
17. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study
18. Immunologic and virologic response to highly active antiretroviral therapy in the multicenter AIDS cohort study
19. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
20. Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: Modulation with differentiation stage and during aging
21. Effect of ABC transporters on HIV-1 infection: Inhibition of virus production by the MDR1 transporter
22. Frequency of C3435T polymorphism of MDR1 gene in African people
23. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
24. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene
25. Identification of functionally variant MDR1 alleles among European Americans and African Americans
26. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells
27. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes
28. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins
29. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted
30. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans
31. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes
32. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors
33. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences
34. MDR1 pharmacogenetics: Frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity